This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia

This study has been completed.
Information provided by:
Office of Rare Diseases (ORD) Identifier:
First received: June 2, 2000
Last updated: June 23, 2005
Last verified: July 2004


I. Determine the effectiveness of moderate dose cyclophosphamide and radiotherapy in terms of improving survival and reducing the morbidity following allogeneic bone marrow transplantation in patients with myelodysplastic syndrome and acute leukemia related to Fanconi's anemia.

Condition Intervention
Fanconi's Anemia Myelodysplastic Syndromes Leukemia, Nonlymphocytic, Acute Leukemia, Lymphocytic, Acute Drug: cyclophosphamide Procedure: Allogeneic Bone Marrow Transplantation

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Office of Rare Diseases (ORD):

Study Start Date: March 2000
Detailed Description:


Patients receive cyclophosphamide IV over 1-2 hours on day -6 through -3 and total body radiotherapy on day -1. Patients undergo allogeneic bone marrow transplantation on day 0.


Ages Eligible for Study:   up to 54 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Diagnosis of Fanconi's anemia with the family history and typical phenotype including: Short stature Hypoplastic radii Skin pigmentation Renal anomalies Chromosomal fragility
  • Evidence of Fanconi's myelodysplastic syndrome Bone marrow dysplasia of all 3 marrow cell lines AND Clonal cytogenetic abnormalities demonstrable in marrow cells
  • First complete remission following therapy for Fanconi's acute leukemia allowed
  • Must have related histocompatible donor No evidence of excessive in vitro chromosome fragility typical of Fanconi's anemia Normal CBC and bone marrow
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00005892

United States, Minnesota
Fairview University Medical Center
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
Fairview University Medical Center
Study Chair: Daniel J. Weisdorf Fairview University Medical Center
  More Information Identifier: NCT00005892     History of Changes
Other Study ID Numbers: 199/15100
Study First Received: June 2, 2000
Last Updated: June 23, 2005

Keywords provided by Office of Rare Diseases (ORD):
Fanconi's anemia
acute leukemia
acute lymphocytic leukemia
acute myeloid leukemia
acute undifferentiated leukemia
adult acute lymphoblastic leukemia
adult acute lymphoblastic leukemia in remission
adult acute myeloid leukemia
adult acute myeloid leukemia in remission
aplastic anemia
childhood acute lymphoblastic leukemia
childhood acute lymphoblastic leukemia in remission
childhood acute myeloid leukemia
childhood acute myeloid leukemia in remission
de novo myelodysplastic syndrome
hematologic disorders
hematopoietic/lymphoid cancer
myelodysplastic syndrome
oncologic disorders
previously treated myelodysplastic syndrome
rare disease
secondary myelodysplastic syndrome

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Fanconi Anemia
Fanconi Syndrome
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Myeloid, Acute
Pathologic Processes
Neoplasms by Histologic Type
Hematologic Diseases
Bone Marrow Diseases
Precancerous Conditions
Anemia, Hypoplastic, Congenital
Anemia, Aplastic
Genetic Diseases, Inborn
DNA Repair-Deficiency Disorders
Metabolic Diseases
Renal Tubular Transport, Inborn Errors
Kidney Diseases
Urologic Diseases
Metabolism, Inborn Errors
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on August 22, 2017